Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : ABT save search
Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001
Published: 2024-01-23 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.46%
H: 0.74%
C: -0.04%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
ceo pharmaceuticals trial
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Published: 2024-01-18 (Crawled : 21:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
first treat global system heart trial
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
Published: 2023-11-07 (Crawled : 13:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
SRDX | News | $26.47 0.3% 0.3% 55K
|
Health Technology
|
| O: 0.69%
H: 1.71%
C: 0.95%
symposium trial transcend
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
Published: 2023-03-05 (Crawled : 16:20) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
device trial show benefits
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.58%
H: 2.53%
C: -0.7%
SRDX | News | $26.47 0.3% 0.3% 55K
|
Health Technology
|
| O: -0.77%
H: 8.9%
C: 4.92%
conference trial transcend
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.14%
H: 1.46%
C: 0.34%
SRDX | News | $26.47 0.3% 0.3% 55K
|
Health Technology
|
| O: 1.29%
H: 3.22%
C: 1.97%
trial transcend
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Infant Formula-Related Securities Fraud Class Action Filed
Published: 2022-09-08 (Crawled : 23:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.13%
H: 1.81%
C: 1.26%
trial
Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials
Published: 2022-05-11 (Crawled : 14:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -2.17%
H: 1.28%
C: -0.77%
trials women one trial
Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
Published: 2022-02-07 (Crawled : 20:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
ema implant trial
Know Labs Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™
Published: 2022-02-03 (Crawled : 15:30) - biospace.com/
KNWN | $2.53
|
Manufacturing
|
| O: 0.0%
H: 1.27%
C: 0.63%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -1.08%
H: 1.79%
C: 1.15%
DXCM | $130.71 -2.67% -2.75% 2.8M
|
Health Technology
|
| O: -0.98%
H: 1.55%
C: -2.94%
technology trial approval
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
Published: 2021-11-12 (Crawled : 14:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
ema trial
Rise in Atrial Fibrillation Cases Demands for Transseptal Access Systems for Reducing Risk and Increase Survival rates
Published: 2021-09-07 (Crawled : 12:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.53%
H: 0.28%
C: 0.21%
risk trial
Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
Published: 2021-08-30 (Crawled : 16:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.05%
H: 1.33%
C: 1.13%
stroke risk device trial
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
Published: 2021-08-16 (Crawled : 12:15) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.91%
H: 0.82%
C: 0.78%
fda stroke risk device trial
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
Published: 2021-05-06 (Crawled : 14:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.39%
H: 0.7%
C: 0.63%
treatment heart trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.